Journal Home
Search for

Volume 15, Issue 9, Pages 770-774 (November 2009)


View previous. 11 of 26 View next.

Antibodies to Oxidized LDL as Predictors of Morbidity and Mortality in Patients With Chronic Heart Failure

Gideon Charach, MD12Corresponding Author Informationemail address, Jacob George, MD1, Arnon Afek, MD, MHA3, Dov Wexler, MD1, David Sheps, MD1, Gad Keren, MD1, Ardon Rubinstein, MD3

Received 22 November 2008; received in revised form 4 May 2009; accepted 7 May 2009. published online 06 July 2009.

Abstract 

Background

Oxidative stress appears to play a significant role in the pathogenesis of heart failure (HF). Antibodies to oxidized low-density lipoprotein (Ox LDL Abs) reflect an immune response to LDL over a prolonged period and may thus represent oxidative stress over an extended time. Ox LDL Abs have been shown to correlate with clinical control in HF patients. We evaluated the predictive power of Ox LDL Abs on the outcome in patients with HF.

Methods and Results

Baseline levels of Ox LDL Abs were determined by enzyme-linked immunosorbent assay in 284 consecutive outpatients with severe chronic HF who were being treated in the cardiology services of our medical center. Their mean New York Heart Association (NYHA) Class was 2.8. The mean follow-up for the group was 3.7 years, during which 107 (37%) died. The mean time from symptom onset to first hospital admission from HF was 25.8 months. Ox LDL Abs were found to predict morbidity and mortality as evaluated by a Cox multivariate regression analysis with a hazard ration of 1.013 (P < .013), whereas N-terminal pro-B-type natriuretic peptide (NT pro-BNP) levels achieved a HR of 1.028 (P < .099).

Conclusions

Ox LDL Abs level maybe a useful parameter for monitoring and planning better management of patients with HF. It was superior to pro-BNP as a predictor of clinical course as expressed by time to hospitalization.

1 Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

2 Internal Medicine “C”, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

3 Lipid Unit, Tel Aviv, Israel, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Corresponding Author InformationCorrespondence to: Gideon Charach, MD, The Department of Cardiology, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv, 64239 Israel. Tel: +972-524-266851; Fax: +972-3-6974990.

 The authors have no conflicts of interest.

PII: S1071-9164(09)00171-7

doi:10.1016/j.cardfail.2009.05.009


View previous. 11 of 26 View next.